selitzin

American Renal Associates Poised to Go Down in Flames

Short
selitzin Updated   
NYSE:ARA   None
ARA very low market share in the dialysis space (3%), and facing competitive disadvantages compared to the bigger players. Also, California Assembly just passed dialysis legislation SB 1156 which caps commercial dialysis payments at lower Medicare rates. On its way to $150....
Comment:
Change price Target to $15 from 150....
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.